Evidence map›Paper›PMID 41281919›Full record

ArticleInternational journal of particle therapy2025

In Silico Comparison of Photon Versus Proton Based Stereotactic Body Radiotherapy With Increasing Maximum Peak Dose for Treatment of Primary Renal Cell Carcinoma.

Sherif G Shaaban, Hao Chen, Anh Tran, Aditya Halthore, Rachit Kumar, Michael Goldstein, Daniel Song, Stephen Greco, Heng Li, Curtiland Deville

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of particle therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Dosimetric impact of daily skin surface variations in kidney stereotactic ablative proton therapy.Technical innovations & patient support in radiation oncology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sherif G ShaabanDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hao ChenDepartment of Radiation Oncology, University of South Florida Healthcare, Tampa, FL, USA.
Anh TranDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Aditya HalthoreDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rachit KumarDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael GoldsteinDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Daniel SongDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Stephen GrecoDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Heng LiDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Curtiland DevilleDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Photon based Stereotactic Body Radiotherapy (PH-SBRT) has emerged as a promising option for treatment of primary renal cell carcinoma (RCC), however is associated with decrements in long-term kidney function and toxicity to adjacent organs at risk (OARs). Materials and Methods: We compared proton (PT) based SBRT versus PH-SBRT regarding target coverage, OARs, and maximum peak doses of 125% and 142%. All variables were compared using student Results: Target coverage was comparable between plans for gross tumor volume (GTV) and clinical target volume (CTV). OARs were greatly spared by PT-SBRT including small bowel; V5 Gy to V25 Gy and maximum dose (10.47, 20.22, Conclusion: PT-SBRT improved target coverage while reducing dose to the involved kidney and adjacent OARs. Protons allow delivery of maximum peak dose escalated plans without exceeding the normal tissues limit and have the potential to better preserve renal function. Prospective studies are warranted to validate these findings and potential clinical benefits.

Indexed as

Proton therapyRenal cell carcinomaSBRT

Identifiers

PMID41281919
PMCPMC12634305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.